Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H4

B7-H4

Brief Information

Name:V-set domain-containing T-cell activation inhibitor 1
Target Synonym:V-Set Domain-Containing T-Cell Activation Inhibitor 1,Immune costimulatory protein B7-H4,B7h.5,B7 homolog 4,T-cell costimulatory molecule B7x,V-Set Domain Containing T Cell Activation Inhibitor 1,B7X,B7 Family Member, H4,T Cell Costimulatory Molecule B7x,B7S1,B7 Superfamily Member 1,VCTN1,PRO1291,FLJ22418,B7H4,B7-H4,Protein B7S1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

B74-C52H9-ELISA
Cynomolgus / Rhesus B7-H4, His TagCynomolgus / Rhesus B7-H4, His Tag (Cat. No. B74-C52H9) ELISA bioactivity

Immobilized Cynomolgus / Rhesus B7-H4, His Tag (Cat. No. B74-C52H9) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H4 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

B74-R52H9-ELISA
Rat B7-H4, His TagRat B7-H4, His Tag (Cat. No. B74-R52H9) ELISA bioactivity

Immobilized Rat B7-H4, His Tag (Cat. No. B74-R52H9) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H4 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

Customer Reviews

Synonym Name

B7-H4,VTCN1,B7S1,B7h.5

Background

V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NC-762 NC-762 Phase 2 Clinical Ovarian Neoplasms; Solid tumours; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
GEN-1047 GEN-1047 Phase 2 Clinical Genmab A/S Ovarian Neoplasms; Carcinoma; Breast Neoplasms; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Alsevalimab FPA-150 Phase 1 Clinical Five Prime Therapeutics Solid tumours; Ovarian Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms; Endometrial Neoplasms Details
SGN-B7H4V SGN-B-7H-4V; SGNB-7H4V; SGNB-7H-4V; SGN-B7H4V Phase 1 Clinical Seagen Inc Ovarian Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PF-07260437(Pfizer) PF-07260437 Phase 1 Clinical Pfizer Inc Ovarian Neoplasms; Breast Neoplasms; Endometrial Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message